Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: A retrospective cross-sectional case-control study from a single center

Rheumatology International

Volumn 32, Issue 1, 2012, Pages 129-135

  Padovan, Melissa ^a   Castellino, Gabriella ^a   Bortoluzzi, Alessandra ^a   Caniatti, Luisa ^b   Trotta, Francesco ^a   Govoni, Marcello ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Central nervous system; Neuropsychiatric lupus; Risk factors; Systemic lupus erythematosus

Indexed keywords

CONTRACEPTIVE AGENT; GLUCOCORTICOID; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NEUROPSYCHIATRY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RISK FACTOR; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; MOOD DISORDERS; PREVALENCE; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; SEIZURES;

EID: 84857117208     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1565-4     Document Type: Article

References (40)

1. ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology (1999) Arthritis Rheum 42:599-608
2. A Unterman JES Nolte M Boaz, et al. 2009 The prevalence of neuropsychiatric syndromes in sle: a metanalysis. 2009 annual scientific meeting of the American college of rheumatology, Philadelphia 16-21 October Arthritis Rheum 60 suppl S589
3. JG Hanly NMG Walsh V Sangalang 1992 Brain pathology in systemic lupus erythematosus J Rheumatol 19 732 741 1613703 1:STN:280:DyaK38zgvFamtw%3D%3D
4. EM Tan AS Cohen JF Fries AT Masi DJ McShone NF Rothfield JG Schaller N Talal RJ Winchester 1982 The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1271 1277 7138600 10.1002/art.1780251101 1:STN:280:DyaL3s%2FkvVCmtA%3D%3D (Pubitemid 13221242)
5. G Castellino M Padovan A Bortoluzzi M Borrelli L Feggi ML Caniatti F Trotta M Govoni 2008 Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement Rheumatology (Oxford) 47 319 323 10.1093/rheumatology/kem354 1:STN:280:DC%2BD1c7hs1SktA%3D%3D (Pubitemid 351267199)
6. Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure (JNC-V1) (1997) Sixth report. Arch Intern Med. 157:2413-2446
7. World Health Organization (1997) Obesity: preventing and managing the global epidemic. World health Organization Geneva
8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
9. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
10. WA Wilson AE Gharavi T Koike MD Lockshin DW Branch JC Piette, et al. 1999 International consensus statement on preliminary classification criteria for definitive Antiphosphilipid syndrome Arthritis Rheum 42 1309 1311 10403256 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F 1:STN:280:DyaK1MzjtVSmsg%3D%3D (Pubitemid 30265586)
11. DA Horbach E Oort RC Donders RH Derksen PG de Groot 1996 Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus (comparison between different assays for the detection of antiphospholipid antibodies) Thromb Haemost 76 916 924 8972011 1:CAS:528:DyaK2sXjvVChtw%3D%3D
12. FB Karassa JPA Ioannidis G Touloumi KA Boki HM Moutsopoulos 2000 Risk factors for central nervous system involvement in systemic lupus erythematosus Q J Med 93 169 174 10.1093/qjmed/93.3.169 1:STN:280:DC%2BD3czpt1CltQ%3D%3D (Pubitemid 30128704)
13. PG Vlachoyiannopoulos FB Karassa KX Karakostas AA Drosos HM Moutsopoulos 1993 Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients Lupus 2 303 312 8305923 10.1177/096120339300200505 1:STN:280:DyaK2c7jvVegsQ%3D%3D
14. SG West W Emlen MH Wener BL Kotzin 1995 Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests Am J Med 99 155 163 10.1016/S0002-9343(99)80135-1
15. E Toubi MA Khamashta A Panarra GR Hughes 1995 Association of antiphospholipid antibody with central nervous system disease in systemic lupus erythematosus Am J Med 99 243 248 10.1016/S0002-9343(99)80188-0
16. G Sanna ML Bertolaccini MJ Cuadrado H Laing MA Khamashta A Mathieu GR Hughes 2003 Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies J Rheumatol 30 985 992 12734893 (Pubitemid 36529618)
17. RL Brey SL Holliday AR Saklad, et al. 2002 Neuropsychiatric syndromes in lupus: prevalence using standardized definitions Neurology 58 1214 1220 11971089 1:STN:280:DC%2BD383jtF2msg%3D%3D (Pubitemid 34411865)
18. J Sastre-Garriga X Montalban 2003 APS and the brain Lupus 12 877 882 14714905 10.1191/0961203303lu496oa 1:STN:280:DC%2BD2c%2FhslChtQ%3D%3D (Pubitemid 38082081)
19. G Sanna ML Bertolaccini MJ Cuadrado MA Khamashta GR Hughes 2003 Central nervous system involvement in the antiphospholipid antibodies syndrome Rheumatology 42 200 213 12595612 10.1093/rheumatology/keg080 1:CAS:528:DC%2BD3sXit1ynt78%3D (Pubitemid 36305604)
20. F Trotta L Dovigo M Govoni, et al. 1997 Neuropsychiatric involvement in systemic lupus erythematosus. A clinical and instrumental study in 116 North Italian Patients Eur J Intern Med 8 95 103
21. F Karassa J Ioannidis K Boki, et al. 2000 Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus Am J Med 109 628 634 11099682 10.1016/S0002- 9343(00)00603-3 1:STN:280:DC%2BD3M%2FltVansA%3D%3D
22. J Mikdashi B Handwerger 2004 Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort Rheumatology 43 1555 1560 15342927 10.1093/rheumatology/keh384 1:STN:280: DC%2BD2crpt1Wqtw%3D%3D (Pubitemid 39642582)
23. JS Sergent MD Lockshin MS Klempner BA Lypsky 1975 Central nervous system disease in SLE: therapy and prognosis Am J Med 58 644 654 1130420 10.1016/0002-9343(75)90500-8 1:STN:280:DyaE2M7mt1Wrug%3D%3D
24. JT Sibley WP Olszynsky WE Decoteau MB Sundaram 1992 The incidence and prognosis of central nervous system in SLE J Rheumatol 19 47 52 1556699 1:STN:280:DyaK383htFKluw%3D%3D
25. Silverman ED HI T To, et al. 2002 Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage Arthritis Rheum 46 436 444 10.1002/art.10072 (Pubitemid 34136581)
26. EJ Feinglass FC Arnett CA Dorsch TM Zizic MB Stevens 1976 Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease Medicine 55 323 339 781466 10.1097/00005792-197607000-00004 1:STN:280:DyaE283kt1eisg%3D%3D
27. CS Yee H Hussein J Skan J Skan S Bowman D Situayake C Gordon 2003 Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus Rheumatology 42 276 279 12595622 10.1093/rheumatology/keg078 1:CAS:528:DC%2BD3sXit1yntLk%3D (Pubitemid 36305614)
28. LE Schiffer N Hussain X Wang W Huang J Sinha M Ramanujam A Davidson 2002 Lowering anti-dsDNA antibodies-what's new? Lupus 11 885 894 12529055 10.1191/0961203302lu311rr 1:CAS:528:DC%2BD3sXnvVWisA%3D%3D (Pubitemid 36069985)
29. MG Tektonidou JPA Ioannidis KA Boki PG Vlachoyiannopoulos HM Moutsopoulos 2000 Prognostic factors and clustering of serious clinical outcomes in antiphospholipid antibodies syndrome Q J Med 93 523 530 10.1093/qjmed/93.8.523 1:STN:280:DC%2BD3cvntValtA%3D%3D (Pubitemid 30623788)
30. EY McLaurin SL Holliday P Williams RL Brey 2005 Predictors of cognitive dysfunction in patients with systemic lupus erythematosus Neurology 64 297 303 15668428 10.1212/01.WNL.0000149640.78684.EA 1:STN:280:DC%2BD2M%2FktFSmtw%3D%3D
31. P Tomietto V Annese S D'Agostini P Venturini G La Torre S De Vita GF Ferraccioli 2007 General and specific factor associated with severity of cognitive impairment in systemic lupus erythematosus Arthritis Rheum 57 1461 1472 18050188 10.1002/art.23098 1:STN:280:DC%2BD2sjltVKktw%3D%3D (Pubitemid 350308845)
32. J Mikdashi A Krumholz B Handwerger 2005 Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus Neurology 64 2102 2107 15985581 10.1212/01.WNL.0000165959.98370.D5 (Pubitemid 40881002)
33. M McNicholl D Glynn AB Mongey M Hutchinson B Bresnihan 1994 A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus J Rheumatol 21 1061 1066 7932416 1:STN:280: DyaK2M%2Fhslyquw%3D%3D (Pubitemid 24182279)
34. G Ferraccioli E Di Poi F Di Gregorio F Giacomuzzi U Guerra 1999 Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud's syndrome Lancet 354 2135 2136 10609825 10.1016/S0140-6736(99)03788-5 1:STN:280:DC%2BD3c%2FnsF2itA%3D%3D (Pubitemid 30008903)
35. A Mathieu G Sanna G Passiu A Cauli M Piga 2000 Raynaud's syndrome in systemic lupus erythematosus Lancet 355 1102 1103 10744119 10.1016/S0140- 6736(05)72227-3 1:STN:280:DC%2BD3c3gsF2rtA%3D%3D (Pubitemid 30162829)
36. V Annese P Tomietto P Venturini S D'Agostini GF Ferraccioli 2006 Migraine in SLE: role of antiphospholipid antibodies and Raynaud's phenomenon Reumatismo 58 50 58 16639488 (Pubitemid 46785286)
37. Y Shoenfeld 2007 To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system J Autoimmun 28 165 169 17382516 10.1016/j.jaut.2007.02.012 1:CAS:528:DC%2BD2sXkvFOlsL0%3D (Pubitemid 46670694)
38. PL Meroni Y Shoenfeld 2008 Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies Autoimmun Rev 7 585 587 18706525 10.1016/j.autrev.2008.08.001 1:CAS:528:DC%2BD1cXhtlemsLfN
39. C Briani M Lucchetta A Ghirardello E Toffanina S Zampieri S Ruggero M Scarlato A Quattrini N Bassi M Ermani L Battistini A Doria 2009 Neurolupus is associated with anti-ribosomal P protein antibodies: an inception color study J Autoimmun 32 79 84 19171463 10.1016/j.jaut.2008.12.002 1:CAS:528: DC%2BD1MXjsVOnsb8%3D
40. A Katzav T Ben-Ziv J Chapman M Blank M Reichlin Y Shoenfeld 2008 Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression) J Autoimmun 31 393 398 18947972 10.1016/j.jaut.2008.09.002 1:CAS:528:DC%2BD1cXhsVeksrzF